CD4 and non-small cell lung carcinoma: Moreover, we have previously reported that, among NSCLC patients with controlled disease after CT, patient groups presenting positive TERT-Th1 responses at baseline have significantly increased OS compared to the non-responders group [221], suggesting that CT increases the effector function of pre-existing CD4+ T immunity by promoting immunogenic cell death and, hence, improving patient survival [222].